Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study - Scorecard - MDSpire

Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study

  • By

  • Joyce Baard

  • Luigi Cormio

  • Ranan Dasgupta

  • Daniele Maruzzi

  • Soroush Rais-Bahrami

  • Alvaro Serrano

  • Bogdan Geavlete

  • Stilianos Giannakopoulos

  • Jean de la Rosette

  • Pilar Laguna

  • March 20, 2024

  • 0 min

Share

Clinical Scorecard: Exploring the Difficulties of Biopsies and Cytology in Upper Tract Urothelial Carcinoma: Findings from a Global Practice Study

At a Glance

CategoryDetail
ConditionUpper Tract Urothelial Carcinoma (UTUC)
Key MechanismsHistologic confirmation and staging via diagnostic ureteroscopy (dURS) with biopsy and urine cytology
Target PopulationAdult patients with suspicion of UTUC
Care SettingMulticenter urology centers performing diagnostic and surgical management

Key Highlights

  • EAU and AUA guidelines emphasize risk stratification into low- or high-risk UTUC to guide kidney-sparing surgery or radical nephroureterectomy.
  • Diagnostic ureteroscopy with biopsy is not routinely performed; biopsy quality and diagnostic yield vary and are influenced by tumor location and size.
  • Urine cytology has limited predictive value but shows some concordance with final pathology grade.

Guideline-Based Recommendations

Diagnosis

  • Perform diagnostic ureteroscopy (dURS) when diagnosis and risk stratification cannot be achieved by imaging or voided urine cytology.
  • EAU recommends dURS preferably without biopsy due to high intravesical recurrence after biopsy.
  • AUA recommends endoscopic evaluation with tissue sampling and cytologic washing when diagnostic and prognostic details are needed.

Management

  • Low-risk UTUC patients may be offered kidney-sparing surgery via ureteroscopy.
  • High-risk UTUC patients are indicated for radical nephroureterectomy.

Monitoring & Follow-up

  • Standardized endoscopic examination and documentation during diagnostic procedures to aid clinical decision-making.

Risks

  • High reported intravesical recurrence after dURS combined with biopsies.
  • Diagnostic yield and accuracy of biopsies and urine cytology remain unclear and variable.

Patient & Prescribing Data

Patients with suspected UTUC undergoing diagnostic ureteroscopy and biopsy

Approximately 63% of patients receiving dURS had biopsies; biopsy specimen quality sufficient in 83.5% with no significant difference by biopsy technique; urine cytology has limited but significant concordance with final tumor grade.

Clinical Best Practices

  • Use diagnostic ureteroscopy selectively when imaging and cytology are inconclusive.
  • Consider tumor size and location when choosing biopsy technique (rigid forceps for ureter tumors, baskets for pyelocaliceal tumors and larger tumors).
  • Combine biopsy and cytology results to improve grading accuracy, defining high-grade disease if either test indicates high grade.
  • Standardize endoscopic examination and documentation to improve diagnostic and prognostic assessment.

References

Original Source(s)

Related Content